It has been suggested that pathologists' diagnostic accuracy and confidence could be improved if they gained access to additional clinical information and in-vivo clinical and dermoscopic images of melanocytic tumors. This study examines the effect of digital training for pathologists in interpreting dermoscopic and clinical skin tumor images. The primary outcome of the upcoming DAHT RCT (Dermoscopy Augmented Histology Trial, a randomized controlled trial) is the diagnostic value (accuracy, sensitivity, and specificity) for the intervention and control group. For this purpose, we need an expert agreeable MPATH-Dx classification and diagnosis for all DAHT cases. The DAHT consensus trial strives to establish this gold standard through a four-phased Delphi-like process. Aim: To establish an expert agreeable MPTAH-Dx classification and diagnosis for all DAHT cases. Data collection of DAHT cases: Department of plastic surgery, Herlev hospital, year 2020-2021 DAHT platform: Made in 2021-2023 by Melatech Consensus agreement: Four dermatopathologists assess all DAHT cases, year 2023-2024
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Gold standard diagnosis by using a Delphi-like process
Timeframe: 3 months